Loading
Life sciences · Phase 4 Trial
ClinicalTrials.gov · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 4 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07633470). This is a study registration, not published results. Lead sponsor: Alpha Cognition, Inc. Recruitment status: RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 150 participants (ESTIMATED). Conditions: Alzheimer Disease. Interventions: DRUG: Zunveyl®. Primary outcome measures: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) , From Week 1 up to Week 12; Percentage of Participants who Discontinued due to AEs , From Week 1 up to Week 12; Number of Participants with Treatment Interruptions or Dose Reductions , From Week 1 up to Week 12; Global Tolerability Score , At Weeks 1, 2, 4, 6, 8 12, and 17. Brief summary: The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.